The Laurus Labs Q2 results are a financial story, but the technology behind them is scientific: the company says it has commissioned its first commercial-scale peptide plant at Visakhapatnam and is buying into oligonucleotide technology through Galenvs Sciences. For the quarter ended 30 September 2026, Laurus reported net profit of ₹441 crore, up 126%, on revenue of ₹2,206 crore, up 33%, with contract development and manufacturing (CDMO) revenue up 75% to ₹904 crore. This article looks at the capabilities behind that growth, what peptide and oligonucleotide manufacturing involves, and what the company has not yet shown.
Laurus Labs Q2 results: the science in brief
- CDMO revenue was ₹904 crore, up 75%, and small-molecule CDMO was ₹875 crore, up 86%.
- The company has commissioned its first commercial-scale peptide plant at Visakhapatnam.
- It plans to acquire 60% of Galenvs Sciences, a Canadian oligonucleotide and magnetic nanoparticle firm.
- Research and development spending including capex was ₹183 crore in the first half, 4.3% of revenue.
- Generics revenue was ₹1,302 crore, up 15%.
What the Laurus Labs Q2 results say about small-molecule CDMO
Small-molecule CDMO contributed ₹875 crore of the ₹904 crore CDMO total, up 86%. Small-molecule contract work involves developing synthesis routes for chemical drugs, scaling them from laboratory to commercial volumes and manufacturing them to regulatory standards. It depends on process chemistry skill, safety systems and quality compliance. The company’s results do not name customers or products, so we cannot say which therapy areas drove the increase. Company filings are posted on BSE.
Peptide manufacturing behind the Laurus Labs Q2 results
Peptides are short chains of amino acids used in a growing range of medicines. Making them at commercial scale involves repeated chemical coupling steps, purification and strict impurity control, and often requires specialised equipment. The company says its Visakhapatnam plant is its first commercial-scale peptide facility. Commissioning is an early milestone and revenue from it will depend on customer contracts, regulatory inspections and yields, which the sources do not describe. The company’s main site is at lauruslabs.com.
Why purification is the hard part of the Laurus Labs Q2 results story
In both peptide and oligonucleotide production, each added building block must couple almost perfectly, because small losses at every step compound over a long chain. The result is a mixture that includes the target molecule and closely related impurities such as truncated or modified chains. Separating them requires advanced chromatography and careful analytical testing, and regulators expect manufacturers to characterise and control impurities. This is a general description of the field and not a statement about how Laurus operates its plant. It does explain why capacity, know-how and quality systems, and not only reactors, determine who can win these contracts.
Oligonucleotides and the Laurus Labs Q2 results
Oligonucleotides are short strands of DNA or RNA used in several newer drug classes. Their manufacture also involves stepwise synthesis and demanding purification and conjugation. Galenvs, as described in press reports, works on early-stage oligonucleotide process development, conjugation, advanced purification and magnetic nanoparticle technologies. Laurus chief executive Dr Satyanarayana Chava said it adds differentiated technology capabilities to the TIDES business, the group’s peptide and oligonucleotide unit. The transaction is subject to due diligence, so it is not complete.
Quality and inspection questions after the Laurus Labs Q2 results
New plants usually need to pass customer audits and regulatory inspections before they can supply commercial product, and the timing is often uncertain. A newly commissioned peptide plant therefore represents capacity that has still to be proven. The sources do not report inspection status, batch records or customer qualification for the Visakhapatnam site, and we do not infer them. Readers following the company should look for statements on audits, validation batches and first commercial shipments.
Margins and process efficiency in the Laurus Labs Q2 results
EBITDA margin reached 34.5%, about 850 basis points higher than a year earlier, and gross margin was 63%. Higher margins can reflect higher-value work, better yields or utilisation, but the company did not provide a breakdown in the figures we reviewed. We therefore avoid attributing the gain to any specific technical improvement. By our own calculation, CDMO accounted for about 41% of quarterly revenue.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s HPAPI CDMO Market report values that market at USD 9.40 billion in 2025 and projects more than USD 27 billion by 2035, a CAGR of 11.1% for 2026 to 2035, with oncology the largest application at 68%. North America holds about 38% and Asia Pacific is projected to grow faster, at more than 12.4%. The FAQ’s 2026 value does not fully reconcile with the CAGR, so treat the numbers as estimates. They describe high-potency work, not all of Laurus’s activities.
Timeline of the Laurus Labs Q2 results
- 30 September 2026: quarter ends.
- Late October 2026: results announced.
- Same period: Galenvs deal announced, subject to due diligence.
General background: why new modalities need specialised manufacturing
Newer drug types such as peptides and oligonucleotides cannot always be made in conventional small-molecule plants. Their processes differ, so manufacturers invest in dedicated capacity and expertise. Read more in our Pharmaceutical section.
Our analysis of the Laurus Labs Q2 results
In our assessment, the Laurus Labs Q2 results show that the current earnings come mainly from small-molecule CDMO, while peptides and oligonucleotides are an expansion bet. The scientific and regulatory proof points for that bet lie ahead.
What is not disclosed in the Laurus Labs Q2 results
- Customers, products and contract values.
- Capacity and expected output of the peptide plant.
- Due diligence timeline for Galenvs.
Risks and caveats
This article summarises company results and press accounts and includes general explanation of manufacturing science. It is news reporting and not investment advice.
What to watch next
- Regulatory inspections of the peptide plant.
- Completion of the Galenvs deal.
- Third-quarter CDMO growth.
Questions about the Laurus Labs Q2 results and new modalities
Will peptide revenue be material soon? The sources do not say. Is the Galenvs stake large? The reported investment is small, US$3.75 million. Can oligonucleotide work scale? That is the question the company needs to answer.
FAQ
What did Laurus report?
Net profit of ₹441 crore and revenue of ₹2,206 crore.
What is TIDES?
The group’s peptide and oligonucleotide business.
Is Galenvs complete?
No, it is subject to due diligence.
How we reported this: we relied on the company’s results announcement as reported, public company pages and the Acumen Research and Consulting report cited above. Our calculation is labelled. Last updated 30 October 2026. This is news reporting and not advice.
